Pharmaron Beijing Co., Ltd. (SHE:300759)

Market Cap	50.64B +24.5%
Revenue (ttm)	13.54B +14.8%
Net Income	1.51B -19.7%
EPS	0.86 -19.4%
Shares Out	1.83B
PE Ratio	34.93
Forward PE	27.43
Dividend	0.20 (0.67%)
Ex-Dividend Date	Jul 4, 2025

Volume	15,183,320
Average Volume	20,752,889
Open	29.90
Previous Close	30.73
Day's Range	29.90 - 30.67
52-Week Range	20.47 - 37.63
Beta	0.97
RSI	45.54
Earnings Date	Mar 31, 2026

About Pharmaron Beijing

Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Production Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotide...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 22,908
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300759

Financial Performance

In 2024, Pharmaron Beijing's revenue was 12.28 billion, an increase of 6.39% compared to the previous year's 11.54 billion. Earnings were 1.79 billion, an increase of 12.01%.